Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
Yoshihiko Sakata(Saiseikai Kumamoto Hospital), Shinya Sakata(Kumamoto University Hospital), Yuko Oya(Aichi Cancer Center), Motohiro Tamiya(Osaka International Cancer Institute), Hidekazu Suzuki(Osaka Prefectural Medical Center), Ryota Shibaki(Wakayama Medical University), Asuka Okada(Osaka City General Hospital), Hiroshi Kobe(Kurashiki Central Hospital), Hirotaka Matsumoto(Hyogo Prefectural Amagasaki General Medical Center), Takashi Yokoi(Hyogo Medical University), Yuki Sato(Kobe City Medical Center General Hospital), Takeshi Uenami(Toneyama National Hospital), Go Saito(Chiba University), Yoko Tsukita(Tohoku University), Megumi Inaba, Hideki Ikeda(Chiba University), Daisuke Arai(Saiseikai Utsunomiya hospital), Hirotaka Maruyama(Japan Organization of Occupational Health and Safety), Satoshi Hara(Itami City Hospital), Shinsuke Tsumura(Kumamoto Medical Center), Jun Morinaga(Kumamoto University Hospital), Takuro Sakagami(Kumamoto University Hospital)
Cited by 89
Abstract
Related Papers
No related papers found
Powered by citation graph analysis